Skip to content

Medical emergency? What to do

German insurers review Plavix after negative study

3-RXPublished August 31, 20062 min read

Key points

  • German health insurers, under pressure to cut costs amid reforms, are considering whether to restrict prescription guidelines for Sanofi-Aventis's blood thinner Plavix in a move that could harm the drug's sales.
  • The German Institute for Quality and Efficiency in Healthcare (IQWiG) said clopidogrel, marketed by Sanofi-Aventis and Bristol-Myers Squibb as Plavix or Iscover, offered no benefits over aspirin when used alone as a preventative treatment for conditions resulting from arterial diseases.
  • Sanofi-Aventis, the world's third biggest drugmaker, criticised the institute's report.
  • In the case of clopidogrel, the issue was one of benefit rather than price, the spokeswoman for the B-GA said.

German health insurers, under pressure to cut costs amid reforms, are considering whether to restrict prescription guidelines for Sanofi-Aventis's blood thinner Plavix in a move that could harm the drug's sales.

A spokeswoman for the Joint Committee (B-GA), the self-regulating body of German health insurers, said on Tuesday it was reviewing a report it had commissioned from an independent research institute which questions the benefits of Plavix for certain patients.

The German Institute for Quality and Efficiency in Healthcare (IQWiG) said clopidogrel, marketed by Sanofi-Aventis and Bristol-Myers Squibb as Plavix or Iscover, offered no benefits over aspirin when used alone as a preventative treatment for conditions resulting from arterial diseases.

However, the drug did offer benefits in the long-term treatment of patients with advanced peripheral arterial disease, said the report, released on Friday.

Sanofi-Aventis, the world's third biggest drugmaker, criticised the institute's report. In a statement on its Web site, it said it acknowledged that the drug was advantageous for all patients but that it only showed "additional benefit" for patients with peripheral arterial disease.

Last month, Germany's health insurers acted on a report by IQWiG, which said there was no justification for the higher prices of innovative forms of insulin over traditional ones, forcing manufacturers to cut costs of the newer drugs.

In the case of clopidogrel, the issue was one of benefit rather than price, the spokeswoman for the B-GA said. She noted that the report's findings, if adopted by the B-GA, would form the basis of an advisory to prescribing doctors.

Drug industry lobby groups have warned that many more spending limits on drugs could be on their way as Germany's health insurers are forced to cut costs in the face of a reform that threatens their existence.

Under government proposals for a reform of the 150-billion-euro-a-year ($192 billion) healthcare system, Germany's current 250 health insurers could be reduced to around 50 as the underperforming insurers are swallowed by rivals.

Plavix was launched in 1998. It is currently marketed in over 80 countries, including the United States, through an alliance with Bristol-Myers Squibb (BMS), Sanofi-Aventis says.

Net sales of Plavix in Europe rose 13 percent to 859 million euros in the first six months of 2006.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug Abuse
Cancer

EU to take another look at GSK breast cancer drug

Europe's drugs regulators will take another look at GlaxoSmithKline Plc's new breast cancer pill Tyverb after new data showed a small risk of higher liver enzymes during treatment with the drug. GSK, Europe's biggest…

2 min read

Drug Abuse

Study raises caution on new painkillers

A new class of painkillers that block a receptor called TRPV1 may interfere with brain functions such as learning and memory, a new study suggests. The experiments with rat brain found that the TRPV1 receptor…

4 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.